Component Therapy Flashcards
Component therapy for loss of 25% blood volume and replacement of RBC and plasma volume
Whole blood.
Component therapy for recurrent febrile reactions due to white cell antibodies, CMV transmission reduction, and HLA alloimmunization
Leukoreduced PRBCs (LRPRBC).
Component therapy for plasma protein antibodies, PNH diagnosis, and febrile reactions from leukoagglutinins
Washed RBCs.
Component therapy for reduced exposure to WBCs, platelets, and plasma proteins; long-term storage of rare or autologous units
Frozen/Thawed/Deglycerolized RBCs.
Effect of one unit of PRBC/Whole blood in adults
Increases hemoglobin by 1 g/dL and hematocrit by 3–5%.
Effect of 10–15 mL/kg of PRBC in pediatric patients
Increases hemoglobin by 2–3 g/dL or hematocrit by 6–9%.
Platelet product to correct thrombocytopenia due to decreased function, production, or increased consumption
Random Donor Platelets.
Platelet count increase with random donor platelets transfusion
Increases platelet count by 5,000 to 10,000/µL.
Platelet product for correcting thrombocytopenia in patients with refractoriness to random donor platelets
Single Donor Platelets.
Platelet count increase with single donor platelets transfusion
Increases platelet count by 20,000 to 60,000/µL.
Reason for using single donor platelets in refractoriness cases
Less exposure to foreign antigens due to reduced alloimmunization; more expensive.
Buffy coat method
Hard spin of whole blood, pool buffy coat, soft spin for platelets.
Purpose of agitation
Facilitates oxygen transfer and consumption by platelets.
Corrected Count Increment formula
= Absolute platelet increment/µL × body surface area (m²) / platelets transfused.
Components of Corrected Count Increment
Absolute platelet increment (post transfusion platelet count – pretransfusion platelet count), body surface area (m²), platelets transfused.
Platelets transfused from plateletpheresis
3.0 units.
Platelets in 1 bag
0.55 × number of bags.
Fresh Frozen Plasma (FFP) Contains
All coagulation factors at maximum levels; used for multiple coagulation factor deficiencies.
Storage of FFP
-18°C: 1 year; -65°C: 7 years.
Plasma Frozen within 24 hours (PF24) Contains
All stable proteins of FFP, normal levels of factor V, reduced factor VIII and Protein C.
Thawed Plasma (24 hrs) Used for
Stable clotting factor deficiencies; very low coagulation factors.
Cryoprecipitated Antihemophilic Factor Contains
Factor VIII, fibrinogen, factor XIII, von Willebrand factor, cryoglobulin, fibronectin; thaw at 1–6°C and hard spin.
Cryopoor Plasma (Cryoprecipitate-reduced plasma) Contains
Residual albumin, factors II, V, VII, IX, X, XI, ADAMTS13 (used for Thrombotic Thrombocytopenic Purpura)
Process for Cryopoor Plasma
Thaw at 1–6°C and hard spin, store for 6 hours.
Indication for Granulocyte Concentrate
For CGD, severe neutropenia (<500 PMN/mL), fever unresponsive to antibiotics, and myeloid hypoplasia.
Typical dose of Granulocyte Concentrate
200-600 mL.
Source of Granulocyte Concentrate
Separated from a single unit of whole blood.
How are blood derivatives obtained?
Fractionation of pooled plasma using recombinant DNA or monoclonal antibody purification.
Difference between source plasma and recovered plasma
Source plasma is collected from the donor; recovered plasma is from separated whole blood.
Indication for Normal Serum Albumin (NSA)
For hypovolemic and hypoproteinemic patients, shock, and burn cases.
Examples of synthetic volume expanders
Crystalloids (Ringer’s Lactate, NSS), Colloids (Dextran, HES).
